Regenxbio

RGNX

Market cap $470M

ROCKVILLE, Md., March 2, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Leerink Partners Global Healthcare Conference Fireside Chat: Monday, March 9 at 9:20am ET Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Fireside Chat: Tuesday, March 10 at 1:30pm ET Location: Miami, FL RBC Inaugural Virtual Ophthalmology Conference Fireside Chat: Tuesday, March 24 at 8:45am ET Location: Virtual Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com.

NEW YORK, March 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the important April 14, 2026 lead plaintiff deadline.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 27, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

LOS ANGELES, Feb. 27, 2026 /PRNewswire/ --  The DJS Law Group  reminds investors of a class action lawsuit against  REGENXBIO Inc. ("Regenxbio " or "the Company") (NASDAQ: RGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

LOS ANGELES, Feb. 27, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2026.

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PayPal Holdings, Inc. (NASDAQ:PYPL) and REGENXBIO Inc. (NASDAQ:RGNX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the important April 14, 2026 lead plaintiff deadline.

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

New class action for REGENXBIO (RGNX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Apr. 14, 2026.

LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion.